Most importantly, we first measured differential expression of EIF3H in HCC tumor samples and non-tumorous normal tissue samples and we associated elevated EIF3H expression and clinical outcomes in early stage HCC patients. Here, EIF3H is linked to hepatocellular carcinoma.